Shandong Buchang Pharmaceuticals Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

2,804.75

2,878.89

2,784.95

2,491.39

3,082.73

2,791.12

2,640.56

Other Operating Income

0.00

Total Operating income

2,804.75

2,878.89

2,784.95

2,491.39

3,082.73

2,791.12

2,640.56

Raw Material Cost

1,061.20

1,104.67

1,101.58

855.27

1,393.85

1,326.78

1,174.59

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

28.72

31.13

28.74

34.82

32.21

33.20

29.35

Selling and Distribution Expenses

1,343.09

1,309.26

1,221.38

1,318.52

1,396.20

1,125.17

1,162.18

Other Expenses

4.07

0.49

1.33

12.70

2.26

3.91

1.30

Total Expenditure (Excl Depreciation)

2,473.72

2,449.93

2,365.06

2,335.61

2,844.84

2,524.27

2,379.10

Operating Profit (PBDIT) excl Other Income

331

429

419.90000000000003

155.8

237.89999999999998

266.8

261.5

Other Income

10.64

9.15

25.24

-11.60

-56.48

9.18

23.05

Operating Profit (PBDIT)

289.25

540.86

544.68

-688.34

279.73

374.30

397.18

Interest

28.72

31.13

28.74

34.82

32.21

33.20

29.35

Exceptional Items

10.33

1.30

2.08

0.63

2.17

-1.00

-1.96

Gross Profit (PBDT)

1,743.55

1,774.22

1,683.36

1,636.12

1,688.88

1,464.33

1,465.97

Depreciation

0.00

141.97

153.13

153.52

Profit Before Tax

270.86

369.06

376.05

-875.66

96.56

186.58

212.35

Tax

70.09

73.12

86.24

53.13

61.13

100.13

122.70

Provisions and contingencies

0.00

Profit After Tax

240.62

320.44

307.26

-866.66

81.45

117.40

114.02

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

240.62

320.44

307.26

-866.66

81.45

117.40

114.02

Share in Profit of Associates

0.00

Minority Interest

-39.72

-20.10

-17.37

-53.61

-44.71

-23.96

-26.32

Other related items

0.00

Consolidated Net Profit

200.90

300.34

289.89

-920.27

36.74

93.44

87.70

Equity Capital

0.00

Face Value

1.0

Reserves

10,572.99

10,744.01

10,475.03

10,216.46

11,161.12

11,288.48

11,564.29

Earnings per share (EPS)

0.23

0.3

0.29

-0.82

0.08

0.11

0.1

Diluted Earnings per share

0.23

0.3

0.29

-0.82

0.08

0.11

0.1

Operating Profit Margin (Excl OI)

9.93%

13.54%

13.55%

-33.31%

5.94%

7.58%

8.35%

Gross Profit Margin

9.66%

17.75%

18.6%

-29.0%

8.1%

12.19%

13.86%

PAT Margin

8.58%

11.13%

11.03%

-34.79%

2.64%

4.21%

4.32%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is -2.58% vs 3.38% in Jun 2025

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is -33.10% vs 3.59% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -47.60% vs 2.37% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is -7.72% vs 8.36% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

Compare Quarterly Results Of Shandong Buchang Pharmaceuticals Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

2,804.75

Other Operating Income

0.00

Total Operating income

2,804.75

Raw Material Cost

1,061.20

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

28.72

Selling and Distribution Expenses

1,343.09

Other Expenses

4.07

0.00

4.07

Total Expenditure (Excl Depreciation)

2,473.72

Operating Profit (PBDIT) excl Other Income

331.02

0.00

331.02

Other Income

10.64

Operating Profit (PBDIT)

289.25

Interest

28.72

Exceptional Items

10.33

Gross Profit (PBDT)

1,743.55

Depreciation

0.00

Profit Before Tax

270.86

Tax

70.09

Provisions and contingencies

0.00

Profit After Tax

240.62

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

240.62

Share in Profit of Associates

0.00

Minority Interest

-39.72

Other related items

0.00

Consolidated Net Profit

200.90

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

10,572.99

Earnings per share (EPS)

0.23

Diluted Earnings per share

0.23

Operating Profit Margin (Excl OI)

9.93%

0.00

9.93%

Gross Profit Margin

9.66%

0.00

9.66%

PAT Margin

8.58%

0.00

8.58%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 280.47 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -2.58% vs 3.38% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -9.02% vs 1.89% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 20.09 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -33.10% vs 3.59% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 447.41% vs -75.15% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 27.86 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -47.60% vs 2.37% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -17.13% vs -19.12% in Sep 2024

Quarterly - Interest

Interest 2.87 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -7.72% vs 8.36% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -10.87% vs -0.31% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 9.93%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024